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Helodermin, a newly isolated peptide from Gila Monster venom, is structurally related to VIP and secretin. 
When used as radioligand, [1Z51]helodermin bound rapidly and reversibly to crude rat liver membranes, 
the dissociation being accelerated by GTP. Competition binding curves of [‘251]helodermin and [‘251]VIP 
with unlabelled peptides showed the following order of decreasing affinity: VIP > helodermin > secretin > 
hpGRF(l-29)-NH2. The shape of binding curves and of concurrent adenylate cyclase activation is 
compatible with the specific labelling, by [‘2’I]helodermin, of a class of high-affinity VIP receptors that 
is capable to stimulate adenylate cyclase. 
Gila Monster venom Helodermin Vasoactive intestinal peptide Secretin 
Growth hormone releasing factor Adenylate cyclase Rat liver membrane 
1. INTRODUCTION 
Helodermin is a recently purified peptide from 
the venom of helodermae lizards [l]. On the basis 
of its biological properties, this peptide is related 
to VIP, secretin, PHI and hpGRF [2]. The N- 
terminal amino acid sequence is His-Ser-Asp (like 
that of VIP and secretin); its amino acid composi- 
tion is compatible with a 36 amino acid peptide 
and includes - like that of VIP - two tyrosine 
residues (personal communication, Dr N. 
Yanaihara, Shizuoka College of Pharmacy, 
Japan). Helodermin recognizes pecific VIP recep- 
tors in rat brain and human heart; it activates 
adenylate cyclase in rat heart through the occupan- 
* To whom correspondence should be addressed 
Abbreviations: VIP, vasoactive intestinal peptide; GRF, 
growth hormone releasing factor; PHI, porcine peptide 
having N-terminal histidine and C-terminal 
isoleucineamide; hpGRF, human pancreatic growth hor- 
mone releasing factor 
cy of receptors that are common for secretin and 
VIP, and can also bind to secretin receptors in 
acini and membranes from rat pancreas [2,3]. It 
was of interest, therefore, to test the binding of 
helodermin to VIP receptors (recognizing secretin 
with low affinity) in rat liver membranes and the 
ensuing adenylate cyclase activation. 
2. MATERIALS AND METHODS 
Helodermin was purified from crude Gila 
Monster venom as in [l]. A crude preparation of 
hepatic plasma membranes was obtained from 
male rats as in [4] and immediately assayed for 
tracer binding and adenylate cyclase activity. 
Helodermin and synthetic VIP (kindly supplied 
by Dr D.H. Coy, Tulane University, New Orleans, 
LA) were similarly iodinated by the chloramine-T 
method as in [5] and purified by cellulose absorp- 
tion and bovine serum albumin elution as in [6]. 
The iodination performed on 3 batches of heloder- 
min gave identical results. The specific radioactivi- 
ty of the tracers was 200-3OO,&i/pg. 
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Binding studies were conducted by microfuge 
centrifugation [4]. The radioactivity offered was 
70000 and 40000 cpm for, respectively, [1251]helo- 
dermin and [1251]VIP. Under all experimental con- 
ditions the radioactivity bound was always less 
than 10% of the radioactivity offered and re- 
mained proportional to the amount of membrane 
protein. Competition curves of unlabelled pep- 
tides were not modified by a 3-fold increase in 
tracer concentration, suggesting that the added un- 
labelled peptide concentration required for a 50% 
inhibition of tracer binding was equal to the disso- 
ciation constant of the peptide [7]. 
Adenylate cyclase activity was determined as in 
[8] as described in [4]. 
Secretin and hpGRF( 1-29)-NH2 were generous 
gifts from, respectively, Dr W. K&rig (Hoechst 
Aktiengesellschaft, Frankfurt/Main) and Dr D.H. 
Coy (Tulane University, New Orleans, LA). 
3. RESULTS 
3.1. Comparative effects of helodermin, VIP, 
secretin and hpGRF on adenylate cyclase 
activity in rat liver membranes 
Helodermin and VIP stimulated rat hepatic 
adenylate cyclase activity to the same maximal 
value (fig.1); the potency of helodermin (Kact, 
2 nM) was, however, 7-fold lower than that of VIP 
(Kact, 0.3 nM). Secretin was as efficient as VIP but 
200-fold less potent (J&, 60 nM). The apparent 
maximal efficacy of hpGRF(l-29)-NH2 was 80% 
that of VIP and the 3 other peptides and its K,,, 
(0.9pM) was 3000-fold lower than that of VIP. 
3.2. Identification of helodermin binding sites on 
rat liver membranes 
1251-Labelled helodermin bound rapidly (fig.2) 
and reversibly (fig.3) to rat liver membranes. Ap- 
parent equilibrium was attained after a 30 min in- 
cubation at 37°C. Non-specific binding, determin- 
ed by incubating the tracer and membranes in the 
presence of 1 PM unlabelled VIP, was low (fig.2). 
The tracer was stable during the incubation period, 
based on a 95% precipitability by trichloroacetic 
acid that did not change significantly after a 
30 min incubation (inset, fig.2). The dissociation 
of the tracer bound was measured after adding 
1 PM unlabelled VIP at equilibrium: this dissocia- 
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Fig.1. Effects of increasing concentrations of VIP (0), 
helodermin (0). secretin (A) and hpGRF( 1 -29)-NHz 
(v) on adenylate cyclase activity of rat liver membranes. 
The results were the means of 3 experiments performed 
in duplicate and were expressed in % of the value 
observed in the presence of 1 pM VIP. For estimating 
maximal activity, the basal activity (22.0 2 1.6 pmol 
cyclic AMP produced. min-’ . mg protein-’ was 
subtracted from the value obtained in the presence of 
1 PM VIP (53.2 +_ 3.4 k pmol cyclic AMP 
produced. min-’ . mg protein-‘). 
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Fig.2. Time course of [‘ZSI]helodermin binding to rat 
liver membranes at 37°C. Specific binding (0) 
represented the difference between total binding (0) 
and non-specific binding (A) observed in the presence of 
1pM unlabelled VIP. The inset represents 
trichloroacetic acid precipitability of the tracer during 
incubation in the presence of membranes. The data 
represent 3 experiments. 
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tion was rapid, 50% of the tracer being released 
after 5 min at 37°C. Addition of 1OpM GTP 
markedly accelerated tracer dissociation, 90010 be- 
ing reIeased after 1 min only at 37°C (fig.3). 
3.3. Comparison of helodermin and VIP binding 
sif es 
The specificity of binding sites was studied by 
comparing competition curves between the two 
tracers and the 4 reference peptides VIP, heloder- 
min, secretin, and hpGRF( l-29)-NHz (fig.4). 
[1251JHelodermin and [1251]VIP binding sites 
recognized the 4 unlabelled peptides. The relative 
affinities of these peptides were similar, their order 
of potency remaining in each case: VIP > heloder- 
min > secretin > hpGRF(l-29)-NH2. Significant 
differences were, however, apparent when con- 
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Fig.3. Time course of dissociation of [‘2’I]helodermin 
bound to rat liver membranes. After a 30 min 
incubation period of tracer and membranes at 37’C, the 
radioactivity bound under control conditions (0) was 
compared to that observed after addition of either 1 gM 
unlabelled VIP (e) or 1 pM unlabelled VIP and 10~M 
sidering the affinities of the unlabelled peptides for 
binding sites. VIP, helodermin, secretin and 
hpGRF( 1-29)-NH2 were, respectively, 8-, 2.5, 20- 
and 6-fold more potent in inhibiting [‘251]heloder- 
min binding than [‘2sI]VIP binding. Furthermore, 
competition curves were steeper when performed 
in the presence of [‘2sI]helodermin than in the 
presence of [‘2sI]VIP, at least with VIP and 
helodermin. The concentrations of the 4 peptides 
provoking a 50% inhibition of [‘251]helodermin 
binding (fig.4, lower panel) were in good agree- 
ment with those required for half-maximal 
adenylate cyclase activation (fig. 1). 
4. DISCUSSION 
GTP (A). The data represent 3 experiments. Unlabelled helodermin recognized all binding 
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Fig.4. Inhibition of [‘251]VIP (upper panel) and 
[‘251]helodermin (lower panel) binding by increasing 
concentrations of unlabelled VIP (0), helodermin (o), 
secretin (A) and hpGRF(l-29)-N& (v). The data are 
expressed as a percentage of tracer bound in the absence 
of unlabelled peptide and are the means of 3 experiments 
performed in duplicate. 
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sites occupied by [‘251]VIP in rat liver membranes 
(fig.4, upper panel). Its efficacy in activating 
adenylate cyclase was similar to that of VIP and 
secretin while its potency was lower than that of 
VIP but higher than that of secretin (fig.1). These 
data confirm that helodermin is a peptide struc- 
turally related to VIP [2]. 
VIP receptors in rat liver membranes are 
heterogeneous and can be resolved into a high- 
affinity (&, 0.8 nM) and a low-affinity (&, 9 nM) 
class of receptors [4]. Based on competition 
curves, it appears that [‘251]helodermin specifically 
labelled the high-affinity class of VIP binding sites 
(fig.4). By contrast, the competition curves of 
unlabelled helodermin and VIP with [1251]VIP 
were parallel so that [‘251]helodermin discrim- 
inated the two classes of VIP receptors better than 
unlabelled helodermin. 
[‘251]Helodermin may, thus, be a useful tool to 
study selectively the properties of high-affinity 
VIP receptors in rat liver membranes. These high- 
affinity VIP receptors recognized the parent pep- 
tides helodermin, secretin and hpGRF and their 
occupancy, like that of all VIP receptors [9], was 
markedly reduced by GTP due to an increased 
dissociation rate of the bound peptide (fig.3). The 
excellent correlation between binding data and 
adenylate cyclase activation suggests that the oc- 
cupancy of these high-affinity sites was responsible 
for adenylate cyclase activation. 
Due to the structural homology of hpGRF with 
the VIP family of peptides [lo- 121, hpGRF( 1-29)- 
NH2 was able to recognize high- as well as low- 
affinity VIP receptors in rat liver membranes and 
was capable of activating adenylate cyclase with an 
efficacy close to that of VIP (figs. 1,4). The Kd and 
Kact of hpGRF(l-29)-NH2 on rat liver membranes 
were similar to those observed for VIP receptors in 
membranes from rat intestinal epithelial cells 
where this peptide is only a weak partial agonist 
1131. 
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